Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774436 | 0.92 | SLC5A2 (0.34) | TACR2SSTR4NT5E | |
| SCHEMBL1775976 | 0.91 | CLK1 (0.37) | TACR2SSTR4SSTR1SSTR2SSTR3 | |
| SCHEMBL1776117 | 0.91 | TP53 (0.32) | SSTR4 | |
| SCHEMBL1775301 | 0.91 | TP53 (0.32) | SSTR4 | |
| SCHEMBL2132859 | 0.82 | PTPN1 (0.35) | TACR2SSTR4NT5E | |
| SCHEMBL12605359 | 0.80 | HTR1A (0.34) | TACR2SSTR4NT5E | |
| SCHEMBL1773968 | 0.80 | TACR2 (0.38) | TACR2SSTR4NT5ESSTR1SSTR2 | |
| SCHEMBL1774673 | 0.80 | SLC5A2 (0.34) | TACR2 | |
| SCHEMBL12605356 | 0.80 | TACR2 (0.37) | TACR2SSTR4NT5ESSTR1SSTR2 | |
| SCHEMBL5517833 | 0.79 | SLC5A2 (0.38) | TACR2SSTR4SSTR1SSTR2SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943748-B2 | Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1803721-A1 | NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | SLC5A1, SLC5A2, GPR119 | TACR2 4114/4885SSTR4 2895/4885NT5E 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.